- Metformin (glucophage, others) use for ≥2 years is tied to lower risk for a composite outcome of 5 neurodegenerative diseases among older patients with type 2 diabetes mellitus (T2DM).
Why this matters
- There is a lack of effective interventions for prevention, treatment.
- Incidence of neurodegenerative diseases was 7.16% over a median 5.2-year follow-up.
- Incidence rate per 1000 person-years:
- 11.48 among metformin users.
- 25.45 among metformin nonusers.
- When nonusers were the comparator, risk was lower for patients using drug for:
- 2-4 years (aHR=0.62; 95% CI, 0.45-0.85).
- >4 years (aHR=0.19; 95% CI, 0.12-0.31).
- No significant effect with use for ≤1 year or for 1-2 years.
- Risk reductions greatest for dementia, Parkinson’s disease.
- Retrospective cohort study among 5530 US veterans aged ≥50 years at the time of type 2 diabetes diagnosis who used insulin during at least two-thirds of follow-up, were initially free of neurodegenerative diseases, other mental disorders.
- Propensity score weighting was applied to metformin use groups.
- Main outcome: neurodegenerative diseases (dementia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, mild cognitive impairment).
- Funding: None.
- Lack of information on serum vitamin B12 level.
- Limited ability to assess medication exposure, neurodegenerative disease outcomes.
- Low incidence of some diseases.
- Unclear generalisability.